The TARGET BP I Clinical Trial
Together, the Peregrine System Infusion Catheter and Ablative Solutions dehydrated alcohol make up the Peregrine System Kit which is used during the Peregrine Procedure.
Under an Investigational New Drug (IND) application, Ablative Solutions is studying the investigational Peregrine System Kit for transcatheter alcohol-medicated renal denervation for the treatment of uncontrolled hypertension with targeted delivery of alcohol.
The global TARGET BP I trial is a multi-center, blinded, randomized, sham-controlled trial to evaluate the safety and efficacy of ASI’s drug-device combination therapy for the treatment of uncontrolled hypertension despite pharmacologic treatment, in conjunction with antihypertensive medical therapy. Enrollment in the company’s randomized global TARGET BP I multi-center trial will begin in U.S. and European centers in 2019.
Data from the TARGET BP I trial will be used to seek approval in the United States for the product's use for the treatment of hypertension, in conjunction with medical therapy.